Tumor necrosis factor alpha sensitizes spinal cord TRPV1 receptors to the endogenous agonist N-oleoyldopamine.
Modulation of synaptic transmission in the spinal cord dorsal horn is thought to be involved in the development and maintenance of different pathological pain states. The proinflamatory cytokine, tumor necrosis factor alpha (TNFalpha), is an established pain modulator in both the peripheral and the central nervous system. Up-regulation of TNFalpha and its receptors (TNFR) in dorsal root ganglion (DRG) cells and in the spinal cord has been shown to play an important role in neuropathic and inflammatory pain conditions. Transient receptor potential vanilloid 1 (TRPV1) receptors are known as molecular integrators of nociceptive stimuli in the periphery, but their role on the spinal endings of nociceptive DRG neurons is unclear. The endogenous TRPV1 receptor agonist N-oleoyldopamine (OLDA) was shown previously to activate spinal TRPV1 receptors. In our experiments the possible influence of TNFalpha on presynaptic spinal cord TRPV1 receptor function was investigated. Using the patch-clamp technique, miniature excitatory postsynaptic currents (mEPSCs) were recorded in superficial dorsal horn neurons in acute slices after incubation with 60 nM TNFalpha. A population of dorsal horn neurons with capsaicin sensitive primary afferent input recorded after the TNFalpha pretreatment had a basal mEPSC frequency of 1.35 +/- 0.20 Hz (n = 13), which was significantly higher when compared to a similar population of neurons in control slices (0.76 +/- 0.08 Hz; n = 53; P < 0.01). In control slices application of a low concentration of OLDA (0.2 uM) did not evoke any change in mEPSC frequency. After incubation with TNFalpha, OLDA (0.2 uM) application to slices induced a significant increase in mEPSC frequency (155.5 +/- 17.5%; P < 0.001; n = 10). Our results indicate that TNFalpha may have a significant impact on nociceptive signaling at the spinal cord level that could be mediated by increased responsiveness of presynaptic TRPV1 receptors to endogenous agonists. This could be of major importance, especially during pathological conditions, when increased levels of TNFalpha and TNFR are present in the spinal cord.
Spicarova
Diana
D
Department of Functional Morphology, Institute of Physiology, Academy of Sciences of the Czech Republic, Prague, Czech Republic.
Palecek
Jiri
J
D000704:Analysis of Variance; D000818:Animals; D004298:Dopamine / Q000031:analogs & derivatives* / Q000494:pharmacology; D019706:Excitatory Postsynaptic Potentials / Q000187:drug effects / Q000502:physiology; D008297:Male; D055369:Miniature Postsynaptic Potentials / Q000187:drug effects / Q000502:physiology; D018408:Patch-Clamp Techniques; D020671:Posterior Horn Cells / Q000187:drug effects* / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D013116:Spinal Cord / Q000187:drug effects* / Q000378:metabolism; D009435:Synaptic Transmission / Q000187:drug effects / Q000502:physiology; D050916:TRPV Cation Channels / Q000378:metabolism*; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology*
D050916:TRPV Cation Channels; C494484:TRPV1 receptor; D014409:Tumor Necrosis Factor-alpha; C488796:N-oleoyldopamine; D004298:Dopamine
Arthritis Res Ther. 2005;7(4):R807-16
15987482
Brain Res. 2004 Oct 29;1025(1-2):210-9
15464762
J Neuroimmunol. 2001 Mar 1;114(1-2):48-56
11240015
J Neurosci Res. 2008 Oct;86(13):2867-75
18543334
Brain Res. 1997 Jun 6;759(1):50-7
9219862
Eur J Neurosci. 2003 Feb;17(4):791-804
12603269
Brain Res. 1998 Feb 16;784(1-2):154-62
9518588
J Biol Chem. 2003 Apr 18;278(16):13633-9
12569099
Exp Neurol. 1998 May;151(1):138-42
9582261
J Physiol. 2007 Jan 15;578(Pt 2):397-411
17038422
Neurosci Lett. 2003 Aug 28;347(3):179-82
12875915
J Neuroinflammation. 2010 Feb 10;7:11
20146792
Pain. 2006 Aug;123(3):306-321
16675114
Eur J Neurosci. 2004 Jul;20(2):467-73
15233755
J Neurosci. 1997 Feb 1;17(3):975-82
8994052
J Neurophysiol. 2009 Jul;102(1):234-43
19369364
Cell Mol Neurobiol. 2006 Oct-Nov;26(7-8):1205-17
16705482
Spine (Phila Pa 1976). 2004 May 15;29(10):1082-8
15131433
Arthritis Rheum. 2010 May;62(5):1308-18
20213802
Neuroscience. 2008 Aug 13;155(2):503-9
18582539
Nature. 1999 Jul 29;400(6743):452-7
10440374
Mol Cell Neurosci. 2007 Nov;36(3):381-91
17851089
J Comp Neurol. 2001 Oct 15;439(2):127-39
11596043
J Neurosci. 2008 May 7;28(19):5072-81
18463260
Pain. 2008 Feb;134(3):277-284
17533116
Exp Neurol. 2005 Apr;192(2):444-62
15755561
Brain Res. 2009 May 1;1268:38-47
19285051
J Neurosci. 2008 May 14;28(20):5189-94
18480275
J Neurosci. 2008 Oct 15;28(42):10482-95
18923025
Proc Natl Acad Sci U S A. 2002 Jun 11;99(12):8400-5
12060783
Handb Exp Pharmacol. 2007;(179):155-71
17217056
J Physiol. 2003 May 15;549(Pt 1):231-42
12679376
Nat Rev Neurosci. 2005 Jul;6(7):521-32
15995723
J Neuroinflammation. 2010 Apr 16;7:27
20398373
Neuropharmacology. 2002 Jan;42(1):93-106
11750919
Eur J Neurosci. 1999 Mar;11(3):946-58
10103088
J Neurosci. 2002 Jan 15;22(2):536-45
11784800
Science. 2002 Mar 22;295(5563):2282-5
11910117
Exp Neurol. 2003 Oct;183(2):286-97
14552870
J Neurosci. 2004 Oct 27;24(43):9623-31
15509749
Proc Natl Acad Sci U S A. 2000 May 23;97(11):6155-60
10823958
J Neurosci. 2009 Apr 1;29(13):4096-108
19339605
Physiol Res. 2008;57 Suppl 3:S69-S77
18481913